FGF9 alleviates diabetic cardiomyopathy by activating Nrf2 via SQSTM1/p62-Keap1 in mice
7.5
来源：
Nature
关键字：
ML brain science
发布时间：
2025-11-26 03:42
摘要：
FGF9 has been identified as a potential therapeutic target for diabetic cardiomyopathy (DCM), demonstrating its ability to activate Nrf2 signaling through autophagy. In diabetic mouse models, FGF9 treatment improved cardiac function, reduced hypertrophy, and alleviated oxidative stress. The study highlights the significance of FGF9 in regulating myocardial health and suggests its role in future therapeutic strategies for managing DCM.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.5分+0.5分
scientific_rigor
1.5分+1.0分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
FGF9 ameliorates DCM via non-canonical autophagy-dependent activation of Nrf2.
FGF9 treatment significantly reduced HG + PA-induced cell hypertrophy.
FGF9 overexpression improved LV systolic function in db/db mice.
真实性检查
否
AI评分总结
FGF9 has been identified as a potential therapeutic target for diabetic cardiomyopathy (DCM), demonstrating its ability to activate Nrf2 signaling through autophagy. In diabetic mouse models, FGF9 treatment improved cardiac function, reduced hypertrophy, and alleviated oxidative stress. The study highlights the significance of FGF9 in regulating myocardial health and suggests its role in future therapeutic strategies for managing DCM.